MicroPort® MedBot™’s Toumai® SP Laparoscopic Surgical Robot Receives NMPA Market Approval in China

Shanghai, China, 20 March 2025 —— MicroPort^® MedBot™ is proud to announce that its Toumai^® SP Laparoscopic Surgical Robot has received market approval from the National Medical Products Administration (NMPA) (registration no. 20253010347) in China. This groundbreaking surgical robot is approved for clinical use across a variety of departments, including urology, general surgery, and gynecology.

The Toumai^® SP boasts an innovative, highly integrated single-port design that enables a 2.5cm incision at the belly button, through which three snake-shaped instruments and a snake-shaped endoscope can be inserted. This compact approach excels in complex environments, such as narrow spaces and intricate anatomical structures.

With its small footprint, high adjustability, and minimal space requirements, the robot is  ideal for operating rooms with limited space, improving adaptability in the surgical environment.

Other key features of Toumai^® SP include: 

• Multi-degree-of-freedom Snake-shaped Instruments: Toumai^® SP features a 3D high-definition flexible electronic endoscope designed with a multi-degree-of-freedom snake-shaped structure. This design provides a wide field of view and eliminates blind spots. With high-quality imaging, low latency, dual-lens synchronous focusing, and personalized pupil distance calibration, it ensures stable images and smooth operation. The endoscope also offers multiple control modes, an extended lifespan, and helps reduce surgical costs.
• Crossed Dual C-arm: Toumai^® SP adopts crossed dual C-arm technology, enabling a safer fixed-point design. This allows surgeon to precisely control dual robotic arms through a single minimally invasive incision, supporting full abdominal and pelvic surgeries with enhanced flexibility. By eliminating the need for patient repositioning, it helps reduce the risk of tissue damage.

This approval marks the launch of MicroPort^® MedBot™’s fifth surgical robot, further expanding its portfolio of innovative robotic solutions across various specialties and surgical approaches.

About MicroPort^® MedBot™   

Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort^® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort^®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort^® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.

More information is available at: www.medbotsurgical.com/en